

Award Number: W81XWH-04-1-0543

TITLE: PET and Hormone Receptor Ligands in Breast Cancer

PRINCIPAL INVESTIGATOR: Mary Gemignani, M.D.

CONTRACTING ORGANIZATION: Memorial Sloan-Kettering Cancer Center
New York, NY 10017

REPORT DATE: May 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-05-2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 29 Apr 2004 - 28 Apr 2006	
4. TITLE AND SUBTITLE PET and Hormone Receptor Ligands in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0543	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mary Gemignani, M.D. E-Mail: drakel@MSKCC.ORG				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Memorial Sloan-Kettering Cancer Center New York, NY 10017				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: F-18 labeled estradiol has been found to be useful in the evaluation of estrogen receptor status in patients with breast cancer using PET. To investigate this further, this project's objectives are: <ul style="list-style-type: none"> • To evaluate the use of estrogen-like ligands labeled with positron emitters in preoperatively determining the ER status of breast cancer using PET. • Correlate the ER positivity seen on PET imaging with ER positivity found on pathologic analysis of the surgical specimen. <p>This "proof-of-concept" study is a pilot study designed to determine feasibility of PET imaging. If the study is positive, i.e. if more than 70% of ER+ lesions are positive on PET imaging, we will subsequently plan a study with outcome parameters. PET scans will be graded as negative or positive (defined as tumor:normal uptake ratios of >1.5:1) and ER status will also be graded as negative or positive (defined as staining of > 5% tumor cells in an average high power field). Paired t-test comparison of tumor IHC and PET findings will be carried out. Gamma well counting will be used to quantify uptake of radioactivity in tumor and normal tissue including serum, and expressed as percent injected dose/gram. Serum estradiol is being measured to observe a possible relationship between serum estradiol levels and targeting of radiotracer.</p>					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	5	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5

Introduction

As stated above F-18 labeled estradiol has been found to be useful in the evaluation of estrogen receptor status in patients with breast cancer using PET. To investigate this further, this project's objectives are:

- To evaluate the use of estrogen-like ligands labeled with positron emitters in preoperatively determining the ER status of breast cancer using PET.
- Correlate the ER positivity seen on PET imaging with ER positivity found on pathologic analysis of the surgical specimen.

This "proof-of-concept" study is a pilot study designed to determine feasibility of PET imaging. If the study is positive, i.e. if more than 70% of ER+ lesions are positive on PET imaging, we will subsequently plan a study with outcome parameters.

PET scans will be graded as negative or positive (defined as tumor:normal uptake ratios of $>1.5:1$) and ER status will also be graded as negative or positive (defined as staining of $> 5\%$ tumor cells in an average high power field). Paired t-test comparison of tumor IHC and PET findings will be carried out.

Gamma well counting will be used to quantify uptake of radioactivity in tumor and normal tissue including serum, and expressed as percent injected dose/gram.

Serum estradiol is being measured to observe a possible relationship between serum estradiol levels and targeting of radiotracer.

Body

There have been no patients accrued to this trial to date. Delays occurred due to inquiries for clarification by our internal Research Council, Institutional Review Board and Radioactive Drug Research Committee (RDRC). A complete rewrite was required to address questions as raised by Committee Members. The protocol has been revised and was approved by the final committee- RDRC on 12/21/05. The study was subsequently placed on administrative hold while the PI was out on maternity leave. The IRB approved protocol and consent was forwarded to the Army and reviewed by the U.S. Army Medical Research and Materiel Command Human Subjects Research Review Board (HSRRB) on March 22, 2006. Recommendations and required changes were addressed and the revised protocol and consent were submitted to HSRRB on May 10, 2006. We are still awaiting final approval by the HSRRB. Once approved by HSRRB, an amendment incorporating HSRRB's suggested changes will be submitted to our IRB to be reviewed. After IRB approval enrollment will begin. We anticipate enrolling the first five patients within 3-6 months and will plan to review the results with the RDRC committee in February 2007.